实验药丸降低抗恒定病病人的胆固醇“坏”胆固醇,显示出预防心脏病的希望。 An experimental pill lowers "bad" cholesterol in statin-resistant patients, showing promise for heart disease prevention.

一种实验性每日药丸在不对他类药物有充分反应的患者中降低LDL ("坏") 胆固醇, 目标是不同的代谢途径. An experimental daily pill has shown promise in lowering LDL ("bad") cholesterol in patients who don’t respond adequately to statins, targeting a different metabolic pathway. 早期临床试验结果表明,具有有利安全特征的LDL大幅降低,为高危个人提供了潜在的新选择。 Early clinical trial results indicate significant reductions in LDL with a favorable safety profile, offering a potential new option for high-risk individuals. 虽然需要进行更大规模的长期研究,但研究结果引起了心脏病学家的兴趣,他们寻求更好的工具来防治心脏病,而心脏病是美国最主要的死亡原因。 While larger, long-term studies are needed, the findings have generated interest among cardiologists seeking better tools to combat heart disease, the leading cause of death in the U.S.